CoChat
Sign Up
Cited by 422Dementia and Cognitive Impairment ResearchPharmaceutical Practices and Patient OutcomesGeriatric Care and Nursing Homes

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia

Tariot, Pierre N., Erb, Rosemary, Podgorski, Carol Ann, Cox, Christopher, Patel, Shirish, Jakimovich, Laura, Irvine, Carrie·1998·American Journal of Psychiatry
DOI 10.1176/ajp.155.1.54
Open this paper in CoChat — free account

Abstract

Objective The efficacy, safety, and tolerability of carbamazepine in the treatment of agitation and aggression associated with dementia were assessed. Method In a 6-week, randomized, multisite, parallel-group study of 51 nursing home patients with agitation and dementia, individualized doses of carbamazepine were compared with placebo. Except for a physician monitor and a pharmacist, all participants were blind to treatment. The primary outcome measures were the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression (CGI) global improvement rating. Secondary measures included measures of behavior, aggression, cognition, functional status, staff time, safety, and tolerability. Intent-to-treat analysis was performed. Results The modal carbamazepine dose at 6 weeks was 300 mg/day, and a mean serum level of 5.3 micrograms/ml was achieved. The study was terminated after a planned interim analysis showed that carbamazepine provided more benefit than did placebo. Over 6 weeks the mean total BPRS score decreased 7.7 points for the carbamazepine group and 0.9 for the placebo group, and the weekly scores showed a gradual divergence between the two groups. CGI ratings showed global improvement in 77% of the patients taking carbamazepine and 21% of those taking placebo. Secondary analyses confirmed that the positive changes were due to decreased agitation and aggression. The drug was generally well tolerated, and no change in cognition or functional status occurred. The per…

Overview

Integrity signals

Registry

Crossref · 10.1176/ajp.155.1.54

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Research works printed but not linked: 3

  1. Reisberg B, Franssen E, Sclan SG: Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neuroscience 1989; 54:95–112
  2. Marx MS, Cohen-Mansfield J, Werner P: A profile of the aggressive nursing home resident. Behavior, Health, and Aging 1990; 1:65–73
  3. Chambers CA, Bain J, Rosbottom R, Ballinger BR, McLaren S: Carbamazepine in senile dementia and overactivity—a placebo controlled double blind trial. IRCS Med Sci 1982; 10:505–506

Cited by

Sorted by citations

Items 401–421 of 421

Related

See all

Metadata

Authors
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C.
Affiliations
University of Rochester Medicine (US)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
1998-01-01
Volume
155
Issue
1
Pages
54-61
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/ajp.155.1.54
OpenAlex
W2140320787
Semantic Scholar
c3da70c064f129607116262314bf832944063d1a
Cited by
422
References
27
Citations by year
2026: 1 · 2025: 7 · 2024: 8 · 2023: 3 · 2022: 38 · 2021: 10 · 2020: 8 · 2019: 12 · 2018: 14 · 2017: 14 · 2016: 8 · 2015: 8 · 2014: 12 · 2013: 10 · 2012: 12
FWCI
13.67
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Institute on Aging (AG 08665, AG-10463, P60AG010463, P30AG008665)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Geriatric Care and Nursing Homes
Keywords
carbamazepine, dementia, agitation, aggression, nursing home residents, antipsychotic efficacy, drug tolerability, safety, Brief Psychiatric Rating Scale, Clinical Global Impression Scale, staff time, individualized dosing
MeSH terms
Aged, Aged, 80 and over, Aggression, Alzheimer Disease, Carbamazepine, Dementia, Drug Administration Schedule, Female, Humans, Male, Nursing Homes, Placebos, Psychiatric Status Rating Scales, Psychomotor Agitation, Dementia, Vascular, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review